-- 在StorageVault Canada (SVI.TO)週三公佈第一季財務業績後，加拿大帝國商業銀行資本市場(CIBC Capital Markets)維持對該公司股票的「中性」評級和5.50加元的目標價。 CIBC表示，StorageVault的第一季業績「基本上符合預期，並證實了其核心自助倉儲平台的穩定性」。該行指出，儘管季節性利潤壓力和便攜式倉儲市場疲軟略微抑制了第一季的業績，但空置單位的租賃和近期擴張的整合工作仍在繼續推進。 分析師Dean Wilkinson表示：“總體而言，我們仍然看好SVI的長期增長戰略和資產負債表狀況，這得益於其穩健的核心自助倉儲平台和嚴謹的資本配置策略。儘管如此，由於近期利好因素有限（人口增長放緩），且估值與美國同行基本一致，我們認為在當前價位維持對該股的‘中性’評級是合理的。” （報告北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究報告。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Price: $4.64, Change: $+0.11, Percent Change: +2.43%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.